S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
S&P 500   3,750.77
DOW   30,303.17
QQQ   319.43
pixel
Log in
NASDAQ:ILMN

Illumina Stock Forecast, Price & News

$432.08
+11.53 (+2.74 %)
(As of 01/27/2021 12:00 AM ET)
Add
Compare
Today's Range
$406.84
Now: $432.08
$434.94
50-Day Range
$337.76
MA: $372.21
$421.00
52-Week Range
$196.78
Now: $432.08
$434.94
Volume2.21 million shs
Average Volume1.26 million shs
Market Capitalization$63.08 billion
P/E Ratio100.25
Dividend YieldN/A
Beta1.14
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in certain markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. Illumina, Inc. was founded in 1998 and is headquartered in San Diego, California.
Illumina logo

MarketRank

Overall MarketRank

1.45 out of 5 stars

Medical Sector

478th out of 1,926 stocks

Analytical Instruments Industry

8th out of 29 stocks

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:ILMN
CUSIP45232710
Phone858-202-4500
Employees7,700
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.54 billion
Cash Flow$9.82 per share
Book Value$31.38 per share

Profitability

Net Income$1.00 billion

Miscellaneous

Market Cap$63.08 billion
Next Earnings Date2/11/2021 (Confirmed)
OptionableOptionable
$432.08
+11.53 (+2.74 %)
(As of 01/27/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ILMN News and Ratings via Email

Sign-up to receive the latest news and ratings for ILMN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Illumina (NASDAQ:ILMN) Frequently Asked Questions

How has Illumina's stock been impacted by Coronavirus?

Illumina's stock was trading at $246.01 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ILMN shares have increased by 75.6% and is now trading at $432.08.
View which stocks have been most impacted by COVID-19
.

Is Illumina a buy right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last twelve months. There are currently 3 sell ratings, 8 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Illumina?

Wall Street analysts have given Illumina a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Illumina wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Francis deSouza's approval rating as Illumina's CEO?

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

When is Illumina's next earnings date?

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for Illumina
.

How can I listen to Illumina's earnings call?

Illumina will be holding an earnings conference call on Thursday, February 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Illumina's earnings last quarter?

Illumina, Inc. (NASDAQ:ILMN) issued its quarterly earnings results on Thursday, October, 29th. The life sciences company reported $1.02 EPS for the quarter, beating analysts' consensus estimates of $0.77 by $0.25. The life sciences company earned $794 million during the quarter, compared to the consensus estimate of $713.97 million. Illumina had a trailing twelve-month return on equity of 15.93% and a net margin of 19.70%. The firm's quarterly revenue was down 12.5% compared to the same quarter last year. During the same period in the prior year, the company earned $1.93 earnings per share.
View Illumina's earnings history
.

What price target have analysts set for ILMN?

19 brokerages have issued 1-year price targets for Illumina's stock. Their forecasts range from $280.00 to $415.00. On average, they anticipate Illumina's share price to reach $333.30 in the next year. This suggests that the stock has a possible downside of 22.9%.
View analysts' price targets for Illumina
or view Wall Street analyst' top-rated stocks.

Who are some of Illumina's key competitors?

What other stocks do shareholders of Illumina own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), The Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Who are Illumina's key executives?

Illumina's management team includes the following people:
  • Mr. Francis A. deSouza, CEO, Pres & Director (Age 49)
  • Mr. Sam A. Samad, CFO & Sr. VP (Age 50, Pay $626.7k)
  • Dr. Joydeep Goswami, Sr. VP of Corp. Devel. & Strategic Planning (Age 49, Pay $384.38k)
  • Ms. Aimee L. Hoyt, Chief People Officer & Sr. VP (Age 49, Pay $864.07k)
  • Mr. Robert P. Ragusa, Sr. VP of Global Quality & Operations (Age 60)
  • Ms. Karen K. McGinnis, VP & Chief Accounting Officer (Age 53)
  • Dr. Alexander Aravanis M.D., Ph.D., Sr. VP & Chief Technology Officer
  • Mr. Steve Phillpott, Sr. VP & Chief Information Officer
  • Ms. Juliet Cunningham, VP of Investor Relations
  • Mr. Charles E. Dadswell, Sr. VP, Gen. Counsel & Sec. (Age 61)

What is Illumina's stock symbol?

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Who are Illumina's major shareholders?

Illumina's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Douglas Lane & Associates LLC (0.23%), Sarasin & Partners LLP (0.13%), KAMES CAPITAL plc (0.13%), New York State Teachers Retirement System (0.12%), Ardevora Asset Management LLP (0.10%) and DAVENPORT & Co LLC (0.10%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina
.

Which institutional investors are selling Illumina stock?

ILMN stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Waverton Investment Management Ltd, Gateway Investment Advisers LLC, Pacer Advisors Inc., New York State Teachers Retirement System, Douglas Lane & Associates LLC, Nisa Investment Advisors LLC, and Chicago Capital LLC. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina
or view top insider-selling stocks.

Which institutional investors are buying Illumina stock?

ILMN stock was acquired by a variety of institutional investors in the last quarter, including Ardevora Asset Management LLP, Retirement Systems of Alabama, Private Capital Advisors Inc., Sarasin & Partners LLP, KAMES CAPITAL plc, CWM LLC, Kestra Advisory Services LLC, and Louisiana State Employees Retirement System.
View insider buying and selling activity for Illumina
or or view top insider-buying stocks.

How do I buy shares of Illumina?

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Illumina's stock price today?

One share of ILMN stock can currently be purchased for approximately $432.08.

How big of a company is Illumina?

Illumina has a market capitalization of $63.08 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis. Illumina employs 7,700 workers across the globe.

What is Illumina's official website?

The official website for Illumina is www.illumina.com.

How can I contact Illumina?

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]

This page was last updated on 1/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.